Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 25, 2022 08:00 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET

ROCHESTER, N.Y., May 25, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
April 21, 2021 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research

ROCHESTER, N.Y., April 21, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
March 11, 2021 08:00 ET | Source: Vaccinex, Inc.

Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference

ROCHESTER, N.Y., March 11, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
February 22, 2021 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology

ROCHESTER, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
February 19, 2021 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform

ROCHESTER, N.Y., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
January 05, 2021 08:00 ET | Source: Vaccinex, Inc.

Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event

ROCHESTER, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
November 13, 2020 08:05 ET | Source: Vaccinex, Inc.

Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Additional data from SIGNAL Huntington’s disease (HD) trial support continued development in HD and in Alzheimer’s disease (AD) Phase 1/2 Study to Evaluate Pepinemab in Combination with KEYTRUDA®...
August 14, 2020 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update

On track to report potentially pivotal Phase 2 Huntington’s disease topline data by early October Phase 1/2 trial of pepinemab in Alzheimer’s disease to begin enrolling patients in September Raised...
June 09, 2020 08:00 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series

Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session ROCHESTER, N.Y., June 09,...
May 14, 2020 08:45 ET | Source: Vaccinex, Inc.

Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update

Approaching key topline data in non-small cell lung cancer and Huntington’s disease Advancing plans to expand pepinemab development to include Alzheimer’s disease ROCHESTER, N.Y., May 14, 2020 ...

Next Page keyboard_arrow_right